Tiered Pricing Strategies in Emerging Markets
For the pharmaceutical industry, emerging markets are dynamic, full of potential and offer solid growth at a time when established markets are contracting. But they also pose a significant problem: extreme disparities in income.
Increasingly, companies are turning to tiered pricing as a solution. The strategy targets market segments, boosts market share and increases patient access to drugs. But it’s not perfect.
Report Overview
Tiered Pricing Strategies in Emerging Markets offers concisely written insights into the issue of differential pricing in fast-growing markets where stark disparities in wealth are common. Based on interviews with experts from pharma, health economics and health activism, the report sheds light on the challenges ahead in establishing the right price point, increasing market access and avoiding the diversion of price-tiered products into wealthier markets while answering the call of corporate social responsibility. Filled with clear explanations and timely examples, the report gives the industry a precise view of a new and highly selective strategy.
Key Report Features
Key Benefits
Key Questions Asked
Who Would Benefit From This Report?
Key quotes
“This issue of access to medicine on a global basis is here to stay. It isn’t only limited to HIV or malaria. It’s something that is going to be an issue for decades to come.” – Suerie Moon, Doctoral Research Fellow at Harvard University’s Center for International Development.
“I think in some markets, say in the least developed of those countries, it's more about trying to show that we are trying our utmost to get access to the products that we make across the board and that we're not specifically focusing on the wealthiest markets.” – Andrew Jenner, Director of Innovation and of Intellectual Property and Trade, IFPMA.
“A major challenge [is] to try and segment the market in a way whereby we can responsibly take advantage of the real commercial opportunities that exist in the growing middle classes in the countries but at the same time try to expand access amongst the poorest communities.” – Jon Pender, Vice President, Government Affairs, Intellectual Property and Access, GSK.
Expert Views
Increasingly, companies are turning to tiered pricing as a solution. The strategy targets market segments, boosts market share and increases patient access to drugs. But it’s not perfect.
Report Overview
Tiered Pricing Strategies in Emerging Markets offers concisely written insights into the issue of differential pricing in fast-growing markets where stark disparities in wealth are common. Based on interviews with experts from pharma, health economics and health activism, the report sheds light on the challenges ahead in establishing the right price point, increasing market access and avoiding the diversion of price-tiered products into wealthier markets while answering the call of corporate social responsibility. Filled with clear explanations and timely examples, the report gives the industry a precise view of a new and highly selective strategy.
Key Report Features
- Insight into the corporate motivation behind tiered pricing
- Discussion of the particular issues posed by determining affordability and segmenting markets in countries with vastly disparate economic profiles
- Examination of alternatives to differential pricing, such as compulsory licensing and generic competition
- Insight into ‘best practices’ for tiered pricing, particularly for non-communicable and chronic diseases
Key Benefits
- Tiered pricing through the eyes of experts in industry, health economics and health activism
- Global overview of pricing differentiation, its benefits and its drawbacks
- Practical strategies and discussion of how the industry can overcome significant hurdles in implementing tiered pricing
Key Questions Asked
- How can tiered pricing be implemented in emerging countries with greatly disparate income levels?
- How can pharma both expand into emerging markets while providing access to affordable drugs?
- What are the ethical and corporate considerations in sustaining effective tiered pricing strategies?
- Who is involved in tiered pricing and what are the outcomes?
- How will tiered pricing be affected as the focus increasingly shifts from communicable to non-communicable diseases?
Who Would Benefit From This Report?
- Market access directors and managers
- Pricing and reimbursement executives
- Key account and territory managers
- Marketing, brand and sales managers
- Business development executives
- Forecasting and marketing professionals
Key quotes
“This issue of access to medicine on a global basis is here to stay. It isn’t only limited to HIV or malaria. It’s something that is going to be an issue for decades to come.” – Suerie Moon, Doctoral Research Fellow at Harvard University’s Center for International Development.
“I think in some markets, say in the least developed of those countries, it's more about trying to show that we are trying our utmost to get access to the products that we make across the board and that we're not specifically focusing on the wealthiest markets.” – Andrew Jenner, Director of Innovation and of Intellectual Property and Trade, IFPMA.
“A major challenge [is] to try and segment the market in a way whereby we can responsibly take advantage of the real commercial opportunities that exist in the growing middle classes in the countries but at the same time try to expand access amongst the poorest communities.” – Jon Pender, Vice President, Government Affairs, Intellectual Property and Access, GSK.
Expert Views
- Jon Pender, Vice President, Government Affairs, Intellectual Property and Access, GlaxoSmithKline, UK
- Robert Sebbag, Vice President, Access to Medicines, Sanofi, France
- Andrew Jenner, Director of Innovation and of Intellectual Property and Trade, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Switzerland
- Suerie Moon, Doctoral Research Fellow, Harvard University Center for International Development, US
- Dr Jorge Mestre-Ferrandiz, Senior Economist, Office of Health Economics, UK
- Dr Mohga Kamal-Yanni, Senior Health and HIV Policy Advisor, Oxfam, UK
EXECUTIVE SUMMARY
PRICING AND ACCESS
Stakeholder and shareholder pressure
Responsible face
Improving access to medicines
Second-line conundrum
Industry’s responsibilities in developing markets
PRICING FOR ACCESS
Emphasizing affordability
Alternatives to differential pricing
Generics and access to medicines
Access to markets
TIERED PRICING IN THEORY
Ramsey and beyond
Recouping R&D costs
The rich must pay for the poor
How elastic is elastic?
Proxy complications
Government responsibility for drug access
An inexact science
TIERED PRICING IN PRACTICE
Who’s doing what
Broadening the scope of tiered pricing
Tiered pricing effect
THE TROUBLE WITH TIERED PRICING
Defaulting to competition, compulsory licenses
Delinking R&D from price
Leakage and external referencing
The drawbacks of transparency
TIERED PRICING FOR THE LONG TERM
Re-engineering the model
ACKNOWLEDGEMENTS
PRICING AND ACCESS
Stakeholder and shareholder pressure
Responsible face
Improving access to medicines
Second-line conundrum
Industry’s responsibilities in developing markets
PRICING FOR ACCESS
Emphasizing affordability
Alternatives to differential pricing
Generics and access to medicines
Access to markets
TIERED PRICING IN THEORY
Ramsey and beyond
Recouping R&D costs
The rich must pay for the poor
How elastic is elastic?
Proxy complications
Government responsibility for drug access
An inexact science
TIERED PRICING IN PRACTICE
Who’s doing what
Broadening the scope of tiered pricing
Tiered pricing effect
THE TROUBLE WITH TIERED PRICING
Defaulting to competition, compulsory licenses
Delinking R&D from price
Leakage and external referencing
The drawbacks of transparency
TIERED PRICING FOR THE LONG TERM
Re-engineering the model
ACKNOWLEDGEMENTS
